We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
The Medicines Company (MDCO) in Focus: Stock Rises 6%
The Medicines Company was a big mover last session, as the company saw its shares rise nearly 6% on the day. The uptrend was driven by the firm’s "highly competitive" phase-one data on a cholesterol-lowering drug with bullish views on it 90 days into phase-two testing. This resulted in solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $35.10 to $41.50 in the past one-month time frame, showed a pick-up yesterday at $37.95.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
The Medicines Company currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is positive.
MEDICINES CO Price
MEDICINES CO Price | MEDICINES CO Quote
A better-ranked stock in the same industry is Axovant Sciences Ltd. (AXON - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MDCO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>